Full Breakdown
Trump’s Executive Order: A Shift in Federal Cannabis Policy
12/26/2025, 10:57:10 PM
Overview of the Executive Order
On December 18, 2025, President Donald Trump signed an executive order directing the Department of Justice (DOJ) to expedite the reclassification of cannabis from a Schedule I to a Schedule III substance under the Controlled Substances Act. This significant policy shift acknowledges cannabis's potential medical uses and lowers its perceived risk of abuse, aligning it with substances like ketamine and anabolic steroids. However, the order does not legalize cannabis at the federal level, and its use remains illegal under federal law.
Implications for the Cannabis Industry
The reclassification could have profound implications for the cannabis industry. Currently, cannabis businesses face significant tax burdens due to Internal Revenue Code Section 280E, which prohibits them from deducting ordinary business expenses. Sam Brill, CEO of Ascend Wellness Holdings, noted that the removal of this restriction could increase profits by approximately 30%. Additionally, the new classification may facilitate access to traditional banking services, allowing dispensaries to process credit and debit card transactions, which are currently restricted due to federal regulations.
Research Opportunities and Challenges
Experts anticipate that the reclassification will enhance medical marijuana research, which has been historically hampered by the stringent regulations associated with Schedule I substances. Neuroscientist Staci Gruber emphasized that the new rules would ease the burdensome licensing process for researchers. However, challenges remain, including the limited sources from which researchers can obtain cannabis for study. Ziva Cooper, director of the Center for Cannabis and Cannabinoids at UCLA, expressed hope that the change could revolutionize public health through more comprehensive research.
Criticism and Opposition
Despite the potential benefits, there are dissenting voices regarding the reclassification. Critics argue that the executive order may complicate efforts to legalize recreational cannabis, as it could create a perception that federal acknowledgment of cannabis's medical benefits diminishes the urgency for broader legalization. Addiction researcher John Gallagher cautioned that while cannabis is less dangerous than Schedule I drugs, it is not without risks, including potential addiction and withdrawal symptoms.
Official Statements and Responses
Mark Hendren, president of Flora Farms in Missouri, remarked that the order allows cannabis companies to operate more like traditional businesses, which could lead to increased investment and growth. Conversely, some lawmakers, like Pennsylvania State Senator Shariff Street, view the reclassification as a long-overdue acknowledgment of cannabis's medical value, while others remain skeptical about its implications for recreational use.
What's Next?
The DOJ is tasked with completing the rulemaking process for the reclassification, which may involve a public comment period. The timeline for implementation remains uncertain, but industry stakeholders are optimistic about the potential for increased research opportunities and financial viability for cannabis businesses. As the regulatory landscape evolves, the cannabis industry will continue to navigate the complexities of federal and state laws.
Verbatim Quotes
- “The biggest thing that happens overnight is the 280E, the restrictive punitive tax code that is set on us," would no longer apply to marijuana businesses, he says.” — Sam Brill, CEO of Ascend Wellness Holdings
- “But there's a lot that will still be challenging in researching cannabis unless we see a lot of agency policies change and adjust.” — Gillian Schauer, Executive Director of the Cannabis Regulators Association
- “Kinkead also spoke in support of Trump’s order: “I know this is a topic that sparks strong opinions on both sides, but if you take an objective look at the guidelines, marijuana should have never been classified as a Schedule I drug.” — State Rep. Emily Kinkead, Pennsylvania
This executive order marks a pivotal moment in U.S. cannabis policy, with the potential to reshape the industry and enhance research capabilities, while also sparking ongoing debates about the future of cannabis legalization.
